# Puhe Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/puhe-biopharma

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.puhebiopharma.com
- Latest round: Series A (Sep 26, 2025)
- Investors on record: 5

## About

Founded in 2020 and based in Suzhou, China, Puhe Biopharma specializes in the research, development, and production of pharmaceutical products. In September 2025, Puhe Biopharma raised Series A funding from investors including Runzhang Investment, Casstar Capital, Trinity Innovation Fund, Hankang Capital, and YuanBio Venture.
Puhe Biopharma specializes in the research, development, and production of innovative pharmaceutical products designed to address unmet clinical needs through differentiated therapeutic mechanisms. The company's core offerings include a range of clinical and preclinical products aimed at targeting specific biological pathways and signaling routes that have not yet been validated through clinical trials. By leveraging deep biological insights, Puhe Biopharma develops next-generation therapeutics, focusing on both proprietary formulation technologies and active pharmaceutical ingredients. The customer base primarily includes healthcare providers, hospitals, and pharmaceutical distributors, with a focus on markets beyond domestic borders, targeting regions such as North America and Europe where there is demand for novel treatment options.
The company's revenue model appears to be anchored in B2B transactions, where the company collaborates with pharmaceutical firms and research institutions to supply its innovative therapeutic products. Transactions typically occur through partnerships or direct sales agreements, where clients may engage in bulk purchasing of unique formulations or active ingredients. Pricing structures are tailored based on the nature of the product and the specifics of the engagement, facilitating flexible arrangements that may involve long-term contracts for ongoing supply. Flagship products are identified within their clinical pipeline, and revenue generation is driven by both upfront payments for initial orders and follow-on purchases as clients integrate these therapeutics into their own portfolios.

## Funding rounds

- Series A, Sep 26, 2025 — YuanBio Venture, Casstar Capital, Hankang Capital, Trinity Innovation Fund, Runzhang Investment

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Series A
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series A
- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Series A
- Runzhang Investment (https://capitalatlas.ai/funds/runzhang-investment) — Series A